PASITHEA THERAPEUTICS CORP (KTTA)
US70261F2020 - Common Stock
PASITHEA THERAPEUTICS CORP
NASDAQ:KTTA (5/6/2024, 10:02:32 AM)
7.05
+0.13 (+1.88%)
Company Profile
Pasithea Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Miami Beach, Florida and currently employs 15 full-time employees. The company went IPO on 2021-08-13. Pasithea Therapeutics Corp. is a biotechnology company. The firm is primarily focused on the discovery, research and development of treatments for Central Nervous System (CNS) disorders and RASopathies. The firm operates through two segments: Therapeutics and Clinics. Its Therapeutics segment performs activities related to the discovery, research, and development of treatments for CNS disorders and other diseases. Its Clinics segment provides business support services to anti-depression clinics in the United Kingdom and in the United States. Its therapeutic pipeline consists of four programs. Its lead product candidate, PAS-004, is a macrocyclic mitogen-activated protein kinase (MEK) inhibitor for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as lamin A/C (LMNA) cardiomyopathy and a number of oncology indications. Its other three programs are in the discovery stage.
Company Info
PASITHEA THERAPEUTICS CORP
1111 Lincoln Road
Miami Beach FLORIDA
P: 17869773380
CEO: Tiago Reis Marques
Employees: 15
Website: https://www.pasithea.com/
KTTA News
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024....
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data....
3 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayPre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments....
4 months ago - Seeking AlphaPasithea conducts 1-for-20 reverse stock split, gets FDA okay for study (NASDAQ:KTTA)Pasithea Therapeutics (KTTA) has conducted a 1-for-20 reverse stock split and received FDA clearance for Phase 1 study of its oncology drug PAS-004. Read more here.
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....
KTTA Twits
Here you can normally see the latest stock twits on KTTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
